UNSPSC 51362007: Flurazepam monohydrochloride

This classification denotes a benzodiazepine with the molecular formula C21H23ClFN3O.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7C4JH842IJ, chemically known as 2h-1,4-benzodiazepin-2-one, 7-chloro-1-(2-(diethylamino)ethyl)-5-(2-fluorophenyl)-1,3-dihydro-, hydrochloride (1:1), but more generally known as flurazepam monohydrochloride, which bears US NIH Compound Identifier 37368.

European Medicines Agency schedules flurazepam monohydrochloride or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07744MIG. Most nations, for tariff purposes, schedule flurazepam monohydrochloride under HS 29339190. Flurazepam monohydrochloride bears US NLM identifiers UMLS ID C0887259 and NCI Concept Code C98134. SMILES: CCN(CC)CCN1C2CCC(CC2C(=NCC1=O)C3CCCCC3F)CL.CL.

UNSPSC 51362007 Flurazepam monohydrochloride, a Commodity code, does not align with the work state and local governments are actually soliciting under this category. The three most recent state and local opportunities posted under this code involve naloxone procurement, direct-to-manufacturer prescription programs, and generic multi-source pharmaceutical distribution — none of which concern flurazepam specifically. The mismatch suggests either a tagging error in the source data or that the code is not actively used for state and local procurement of this specific pharmaceutical at present.

The geographic span of recent activity includes Florida, Texas, and Minnesota through their respective health and human services agencies and cooperative purchasing vehicles. Seminole County, Florida posted an IFB on June 30, 2026 for naloxone and drug deactivation systems with a response deadline of July 26, 2023; the Texas Health and Human Services Commission issued an RFI on April 3, 2026 exploring direct-to-manufacturer prescription models; and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) released an RFP on January 20, 2026 for generic multi-source pharmaceuticals and OTC products across state and local participants, with proposals due March 26, 2026. The absence of recent flurazepam-specific solicitations, combined with the divergence between the code's nominal scope and the opportunities tagged to it, signals that this code warrants monitoring but shows no active demand signal for pursuit at this time.